Sanofi is partnering with Revvity Omics on a rare disease sponsored testing program called 'The Lantern Project', for use by US healthcare providers.
The lantern project covers the cost of testing for several lysosomal disorders, such as Pompe, Fabry, Gaucher, Acid sphingomyelinase deficiency, and MPS-I. This program also includes a few multi-gene panels for disorders such as neuromuscular disease, pain and cerebrovascular disease, and interstitial lung disease.
The Lantern Project is not intended to and should not interfere in any way with a health care professional’s or patient’s independent judgment and freedom of choice in the treatment options for these diseases. Health care professionals and patients should always consider the full range of treatment options and select those most appropriate for the individual patient.
This testing service has not been cleared or approved by the U.S. Food and Drug Administration. Testing services may not be licensed in accordance with the laws in all countries. The availability of specific test offerings is dependent upon laboratory location. The content on this page is provided for informational purposes only, not as medical advice. It is not intended to substitute the consultation, diagnosis, and/or treatment provided by a qualified licensed physician or other medical professionals.
